IP Library Granted Patent US 10,752,686
Granted Patent B2
US 10,752,686 · App. 15/554,476 · Granted Aug 25, 2020

Bispecific antibody binding to human CD26 and human CD3, production method therefor and use thereof

Inventors: Yong Ma (Jiangsu, CN); Peipei Cao (Jiangsu, CN); Anliang Wang (Jiangsu, CN)
Assignees: ZONHON BIOPHARMA INSTITUTE INC.; GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
C07K16/2809A61K39/395A61P35/00C07K16/2896C07K16/30C07K16/46C07K2317/31C07K2317/56C07K2317/732C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,752,686
App. No.
15/554,476
Granted
Aug 25, 2020
Kind
B2
Abstract

Described is a bispecific antibody, and a method for producing the bispecific antibody. The bispecific antibody can be used in the preparation of a drug for treating a tumor with high cell expression of CD26. The antibody specifically hinds to human CD26 and human CD3 at the same time.

Claims (12)

1. A bispecific antibody molecule, comprising a variable domain fragment of an antibody that specifically binds to human CD26, and a variable domain fragment of an antibody that specifically binds to human CD3,

wherein the variable domain fragment that specifically binds to human CD26 comprises a first heavy chain variable domain comprising SEQ ID NO: 1 that specifically binds to human CD26 and a first light chain variable domain comprising SEQ ID NO: 2 that specifically binds to human CD26; and

wherein the variable domain fragment that specifically binds to human CD3 comprises a second heavy chain variable domain comprising SEQ ID NO: 4 that specifically binds to human CD3 and a second light chain variable domain comprising SEQ ID NO: 5 that specifically binds to human CD3.

2. The bispecific antibody molecule according to claim 1 , wherein the first heavy chain variable domain is adjacent to the second heavy chain variable domain; or the first light chain variable domain is adjacent to the second light chain variable domain.

3. The bispecific antibody molecule according to claim 2 , having a polypeptide chain comprising from N-terminus to C-terminus:

a) the first light chain variable domain, the first heavy chain variable domain, the second heavy chain variable domain, and the second light chain variable domain; or

b) the first heavy chain variable domain, the first light chain variable domain, the second light chain variable domain, and the second heavy chain variable domain.

4. The bispecific antibody molecule according to claim 1 , having an amino acid sequence comprising SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10.

5. A method of treating a tumor with high expression of CD26 comprising administering the bispecific antibody molecule of claim 1 to a subject in need thereof.

6. The method according to claim 5 , wherein the tumor is renal cancer, prostatic cancer, colon cancer, or mesothelioma.

7. The bispecific antibody molecule according to claim 1 , wherein the first heavy chain variable domain is adjacent to the second heavy chain variable domain.

8. The bispecific antibody molecule according to claim 2 , having a polypeptide chain comprising from N-terminus to C-terminus, the first light chain variable domain, the first heavy chain variable domain, the second heavy chain variable domain, and the second light chain variable domain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2017
From: MA, YONG; CAO, PEIPEI; WANG, ANLIANG
To: ZONHON BIOPHARMA INSTITUTE INC.; GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
Reel/Frame 043721/0120 →
Continuity (1)
Related Publication 20180155425A1 · Jun 7, 2018
Cited By (1)
US 12,565,529